Overview

Safety and Efficacy Study of YM087 (Conivaptan) in Patients With Acute Decompensated Heart Failure

Status:
Completed
Trial end date:
2004-03-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled, dose ranging pilot study to examine the effects of conivaptan in patients with acute decompensated heart failure.
Phase:
Phase 2
Details
Lead Sponsor:
Cumberland Pharmaceuticals
Treatments:
Conivaptan